Search Orphan Drug Designations and Approvals
-
Generic Name: | brentuximab vedotin | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Adcetris | ||||||||||||||||
Date Designated: | 11/19/2012 | ||||||||||||||||
Orphan Designation: | Treatment of mycosis fungoides | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Seagen Inc. 21823 30th Drive Southeast Bothell, Washington 98021 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | brentuximab vedotin |
---|---|---|
Trade Name: | Adcetris | |
Marketing Approval Date: | 11/09/2017 | |
Approved Labeled Indication: | Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy | |
Exclusivity End Date: | 11/09/2024 | |
Exclusivity Protected Indication* : | Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-